Janice Pauley, MD
Pain Medicine · Dayton, OHNPI 1467488296
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,185 and has fallen 69.2% since, to $365 in 2025.
Across 305 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Abbott$975
- Medtronic$706
- Collegium Pharmaceutical, Inc.$434
- Nevro Corp.$273
- Stimwave Technologies Incorporated$245
- plus $2K from 32 others
What the payments were for
- Travel & lodging$230%
- Food & beverage$6,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,278 |
| Abbott | 46 | $975 |
| Medtronic(2 entities) | 19 | $706 |
| Collegium Pharmaceutical, Inc. | 31 | $434 |
| Nevro Corp. | 11 | $273 |
| Stimwave Technologies Incorporated | 2 | $245 |
| Pfizer | 17 | $243 |
| Vertos Medical, Inc. | 6 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $170 |
| Biohaven Pharmaceuticals, Inc. | 10 | $155 |
| Curonix LLC | 3 | $149 |
| Teva Pharmaceuticals USA, Inc. | 9 | $133 |
| GRT US Holding, Inc. | 10 | $127 |
| Tersera Therapeutics LLC | 7 | $115 |
| Novartis | 7 | $111 |
| Averitas Pharma Inc. | 5 | $102 |
| Boston Scientific | 3 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $68 |
| Scilex Pharmaceuticals Inc. | 4 | $53 |
| IBSA Pharma Inc. | 3 | $44 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Amgen | 3 | $39 |
| Kaleo, Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Saluda Medical Americas, Inc. | 2 | $28 |
| Lilly USA, LLC | 2 | $25 |
| Orexo US, Inc. | 2 | $25 |
| Si-bone, Inc. | 2 | $22 |
| Zyla Life Sciences, Inc. | 2 | $22 |
| Vertex | 1 | $21 |
| Stryker | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Painteq LLC | 1 | $15 |
| SPR Therapeutics, Inc | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| MDD US Operations, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,058 in reported general payments places this provider in the 70th percentile of 245 pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 14 | $9,075 |
| Buprenorphine | 17 | $4,188 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 141 | $3,027 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 134 | $2,396 |
| Pregabalin | 64 | $1,705 |
| Lidocaine | 14 | $1,307 |
| Naloxone Hcl | 13 | $729 |
| Tizanidine Hcl | 73 | $522 |
| Gabapentin | 46 | $496 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $352 |
| Baclofen | 12 | $159 |
| Methocarbamol | 18 | $103 |
| Cyclobenzaprine Hcl | 19 | $92 |
| Tramadol Hcl | 12 | $78 |
| Topiramate | 14 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $434 | $9,07514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 245 pain medicine providers in Ohio.
Other pain medicine in Dayton
- Tammy DannDayton$431K
- Jonathan SilvermanDayton$234K
- Priyesh MehtaDayton$16K
- Alexander EscobarToledo$638K
- Nagy MekhailCleveland$511K
- Henry VuceticWilloughby$509K
- Michael DankoLoveland$381K
- Tristan WeaverColumbus$202K
- Robert BolashCleveland$154K
- Dmitri SouzaCuyahoga Falls$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.